Ipca Laboratories' Piparia facility fails compliance to CGMP

Ipca Laboratories announced that the company has received a communication from US FDA that they have determined the inspection classification of Piparia (Silvassa) formulations manufacturing facility as "Official Action Indicated (OAI)" and that that this facility is considered to be in an unacceptable state of compliance with regards to current good manufacturing practice (CGMP).

Since this manufacturing facility is already under US FDA import alert and presently not doing any US business, this will have no impact on Company's current on-going business activities.

Powered by Capital Market - Live News